All Posts
The Use Of Prostatid In Cancer Detection, Diagnosis And Screening
Overview: ProstatIDTM is North America’s first FDA-Cleared Prostate Cancer SCREENING, Detection and Diagnostic AI software. With 94% AU...
ConcertAI’s TeraRecon and Bot Image, Inc. Partnership
TeraRecon, on March 18, 2023
CAMBRIDGE, Mass., Mar. 18,2023 /PRNewswire/ -- The Eureka Clinical AI platform, from ConcertAI's Tera...
Omaha-Based MRI Medical Device Company, Bot Image, Receives FDA Clearance for AI
FOR IMMEDIATE RELEASE Bot Image, an Omaha-based MRI medical device company has developed an AI-driven medical device CAD software to...
Just released by Dr. Randall W Jones
Just released, The Healthcare Disruptor, by Dr. Randall W Jones. Dr. Jones writes about his journey from rural cowboy to medical device expert and CEO challenging the healthcare system with his inventions...
Bot Image Makes the List: 10 Most Advanced Medical Imaging Solution Providers 2022
Bot Image Inc: Facilitating Early Detection through Disruptive Technology In undetermined and unsettled times, one must be open to...
A Trailblazing Entrepreneur, Bringing Highly Accurate MRI Interpretation Software to Physicians
DR. RANDALL W. JONES FOUNDER & CEO OF BOT IMAGE, INC From joining the military at a young age to excelling at civilian jobs to...
Prostate Cancer Treatment can be safely delayed and inexpensively and accurately monitored thanks to AI
Bot Image, Inc., a Nebraska and Maine based Artificial Intelligence medical device company, has received FDA-clearance on its ProstatID...
ProstatID kick-starts your Prostate MRI program
ProstatID, THE AI software FDA-cleared for not only detection and diagnosis of PCa, but also for screening using bpMRI. Yes, ‘screeni...
New Studies Demonstrate that Bot Image’s Prostate Cancer AI Software Outperforms the Field
Bot Image, Inc., a Nebraska and Maine based Artificial Intelligence medical device company (www.botimageai.com), raised the performance...
Bot Image highlights performance of ProstatID in study
AI medical device company Bot Image is highlighting the performance of its ProstatID in a study evaluating its ability to detect, diagnose, and screen for prostate cancer.